Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these compounds increase insulin release and suppress gluc

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing contrasts in thei